<DOC>
	<DOCNO>NCT01665599</DOCNO>
	<brief_summary>This Phase 3 clinical trial adult hypogonadal male baseline serum testosterone concentration &lt; 300 ng/dL . The purpose study evaluate safety efficacy testosterone gel ( 2 % ) deliver use applicator .</brief_summary>
	<brief_title>A Clinical Trial Evaluate Efficacy Safety Testosterone Gel</brief_title>
	<detailed_description />
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>1 . Males 1875 year age 2 . Two screen serum testosterone value less 300 ng/dL 3 . One symptoms testosterone deficiency 1 . Previous use investigational product 2 . Use investigational product within 30 day prior screen study 3 . BMI le 18 kg/m^2 35 kg/m^2 4 . Prostatic mass ( e ) 5 . Generalized skin irritation skin disease 6 . Lower urinary tract obstruction 7 . Myocardial infarction cerebrovascular accident last 6 month 8 . Unstable angina congestive heart failure 9 . Thromboembolic disorder 10 . Sleep apnea 11 . Hyperparathyroidism uncontrolled diabetes 12 . Untreated moderate severe depression 13 . History testicular , prostate , breast cancer 14 . HIV , Hepatitis B , Hepatitis C positive 15 . PSA equal 3 ng/mL 16 . Use medication could consider anabolic 17 . Use estrogens , Gonadotropin Releasing Hormone agonists/antagonists , antiandrogens , human Growth Hormone 18 . Chronic use drug abuse 19 . Involvement sport screen anabolic steroid 20 . Not willing use adequate contraception study 21 . Partner pregnant and/or breast feed 22 . Partner history breast , uterine ovarian cancer</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>